Prescient Therapeutics raises $7 million to fund cancer treatment pipeline
Biotech Prescient Therapeutics (ASX: PTX) has successfully raised $7 million to fund an expanded pipeline...
Biotech Prescient Therapeutics (ASX: PTX) has successfully raised $7 million to fund an expanded pipeline...
Stockhead’s resident Health and Biotech expert Tim Boreham is putting down the pen and picking...
Prescient Therapeutics (ASX: PTX) Chief Executive Officer Steven Yatomi-Clarke joins Small Caps to discuss the...
Locally-listed small cap biotech company Prescient Therapeutics hopes to shift the conversation around cancer from treatments to...
ASX-listed clinical-stage company Prescient Therapeutics Limited (ASX:PTX) is well-known for developing breakthrough targeted and personalised medicines approaches...
Prescient Therapeutics (ASX:PTX) has formed a cancer research partnership with the world-renowned Peter MacCallum Cancer Centre,...
Prescient Therapeutics (ASX: PTX) has moved closer to developing its unique CAR-T cancer technology after revealing...
Special Report: Biotech company Prescient Therapeutics is advancing to next-stage trials for its personalised treatments...
Every year 45,000 of the most respected professionals in oncology gather at the American Society...
Last month, the best and brightest minds in oncology gathered (virtually) for the American Society...
This investor centre was built by Reach Markets
©2022 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.